Two pharmaceutical conglomerates emerged victorious Friday in a lawsuit accusing the companies of colluding to delay the release of generic medication for sale in a pay-for-delay scheme, say reports.
Pfizer Inc and India-based Ranbaxy Laboratories won a dismissal of the lawsuit filed by retailers and distribution companies. The plaintiffs argued that the two had conspired to delay the release of the generic, cheaper form of Lipitor.
According to reports, the suit alleged that the companies settled a patent dispute in 2008 that saw Pfizer drop patent infringement claims against Ranbaxy and, in exchange, Ranbaxy would not enter the Lipitor market until November 2011.
But a federal judge ruled Friday that the plaintiffs failed to argue the case with sufficient detail, according to reports.
Specifically, the judge ruled that the plaintiffs did not argue a monetary value of the 2008 argument.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI